Statement of intent This document is designed to rationalise the prescribing in this patient group. SCOPE The disease Specialist Nurses are responsible for the day to day management Parkinson’s disease patients both in hospital and in the community. of Parkinson’s The Pharmacists are responsible for specialist advice on specific medicines management and appropriate use of dose calculators. The consultant lead and medical team is responsible for the day to day medical management of disease Parkinson’s The Area Clinical Effectiveness Committee will oversee the ratification of the guideline and appropriate review. 4. DEFINITIONS CK Creatinine Kinase MAO-B Monoamine oxidase B inhibitor NBM Nil by mouth NG Nasogastric NMS Neuroleptic Malignant Syndrome Pd disease Parkinson’s L-Dopa Levodopa COMT Catechol-o-methyl transferase CR Controlled release DUTIES & RESPONSIBILITIES For patients managed in primary care please contact disease Trudy Gaskin (Parkinson’s Nurse Specialist) or Dr Janine Barnes (Neurology Specialist Pharmacist). For secondary care patients please contact Alison Waldron (Acute Clinical Nurse Specialist in disease), Dr Shams Duja (Consultant in Elderly Care) or Dr Alistair Parkinson’s Lewthwaite (Consultant Neurologist). Review and update of this guideline will take place every 3 years. consequences of missing disease drugs parkinson’s Medication is crucial in optimal management of disease. If medication is not Parkinson’s given it can result in the deterioration in patients’ symptoms, including reduced swallow, risk of aspiration, speech problems, increased risk of falls and increased dependence on nursing staff. At worst it may develop into Neuroleptic Malignant Syndrome.
Statement of intent This document is designed to rationalise the prescribing in this patient group. SCOPE The Parkinson’s disease Specialist Nurses are responsible for the day to day management of Parkinson’s disease patients both in hospital and in the community. The Pharmacists are responsible for specialist advice on specific medicines management and appropriate use of dose calculators. The consultant lead and medical team is responsible for the day to day medical management of Parkinson’s disease The Area Clinical Effectiveness Committee will oversee the ratification of the guideline and appropriate review. 4. DEFINITIONS CK Creatinine Kinase MAO-B Monoamine oxidase B inhibitor NBM Nil by mouth NG Nasogastric NMS Neuroleptic Malignant Syndrome Pd Parkinson’s disease L-Dopa Levodopa COMT Catechol-o-methyl transferase CR Controlled release DUTIES & RESPONSIBILITIES For patients managed in primary care please contact Trudy Gaskin (Parkinson’s disease Nurse Specialist) or Dr Janine Barnes (Neurology Specialist Pharmacist). For secondary care patients please contact Alison Waldron (Acute Clinical Nurse Specialist in Parkinson’s disease), Dr Shams Duja (Consultant in Elderly Care) or Dr Alistair Lewthwaite (Consultant Neurologist). Review and update of this guideline will take place every 3 years. consequences of missing parkinson’s disease drugs Medication is crucial in optimal management of Parkinson’s disease. If medication is not given it can result in the deterioration in patients’ symptoms, including reduced swallow, risk of aspiration, speech problems, increased risk of falls and increased dependence on nursing staff. At worst it may develop into Neuroleptic Malignant Syndrome.
Guideline%20-%20swallowing%20ACE%20Jan%202015.docx